

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10568654
Filing Date	2007-02-22
First Named Inventor	Michael Patrick Murphy
Art Unit	1614
Examiner Name	Raymond J. Henley III
Attorney Docket Number	110199.405USPC

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
/R.H./	1	6331532	B1	2001-12-18	Murphy et al.	
	2	6673908	B1	2004-01-06	Stanton Jr., Vincent P.	
	3	6825179	B2	2004-11-30	Nielsen et al.	
	4	6861447	B2	2005-03-01	Moldenhauer et al.	
	5	7109189	B2	2006-09-19	Murphy et al.	
	6	7179928	B2	2007-02-20	Smith et al.	
/R.H./	7	7232809	B2	2007-06-19	Murphy et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS

/Raymond J. Henley III/

10/01/2010

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10568654
Filing Date	2007-02-22
First Named Inventor	Michael Patrick Murphy
Art Unit	1614
Examiner Name	Raymond J. Henley III
Attorney Docket Number	110199.405USPC

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
/R.H./	1	20090258841	A1	2009-10-15	Murphy et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²ⁱ	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
/R.H./	1	0535283	EP	A1	1993-11-22	Merrell Dow Pharmaceutical Inc.		<input type="checkbox"/>
	2	03074395	JP	A	1991-03-28	Nippon Chem Ind Co Ltd		<input type="checkbox"/>
	3	2002104922	JP	A	2002-04-10	Beiersdorf AG+		<input type="checkbox"/>
	4	2003520827	JP	A	2003-07-08	Wacker-Chemie GmbH		<input type="checkbox"/>
	5	2005019233	WO	A1	2005-03-03	Antipodean Biotechnology Limited		<input type="checkbox"/>
/R.H./	6	2009145982	WO	A1	2009-12-03	Antipodean Pharmaceuticals, Inc.		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

/Raymond J. Henley III/

10/01/2010

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10568654
Filing Date	2007-02-22
First Named Inventor	Michael Patrick Murphy
Art Unit	1614
Examiner Name	Raymond J. Henley III
Attorney Docket Number	110199.405USPC

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
/R.H./	1	Asin-Cayuela et al., "Fine-tuning the hydrophobicity of a mitochondria-targeted antioxidant," FEBS Letters 571:9-16, 2004.	<input type="checkbox"/>
	2	Beg et al., "Spectroscopic studies of organophosphorus compounds," Pakistan J. of Scientific and Industrial Research 29(3):165-171, a copy of abstract page 1, 1986.	<input type="checkbox"/>
	3	Kelso et al., "Selective Targeting of a Redox-active Ubiquinone to Mitochondria within Cells," Journal of Biological Chem. 276(7):4588-96, February 16, 2001.	<input type="checkbox"/>
	4	Littaru et al., "In vitro effect of different ubiquinones on the scavenging of biologically generated superoxide," Drugs Under Experimental and Clinical Research 11(8):529-532, Abstract Only, from CAPLUS, Accession Number 1986:2306, page 1 of 1, 1985.	<input type="checkbox"/>
	5	Murphy, Michael P., "Selective targeting of bioactive compounds to mitochondria," Trends in Biotechnology 15 (8):326-330, 1997.	<input type="checkbox"/>
	6	Oliveira et al., "Oxidative stress in the pathogenesis of nonalcoholic fatty liver disease, in rats fed with a choline-deficient diet," J. Cell. Mol. Med. 6(3):399-406, 2002.	<input type="checkbox"/>
	7	Saretzki et al., "MitoQ counteracts telomere shortening and elongates lifespan of fibroblasts under mild oxidative stress," Aging Cell 2:141-143, 2003.	<input type="checkbox"/>
	8	Smith et al., "Delivery of bioactive molecules to mitochondria in vivo," PNAS 100(9):5407-5412, April 29, 2003.	<input type="checkbox"/>
/R.H./	9	Videla et al., "Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients," Clinical Science 106:261-268, 2004.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

/Raymond J. Henley III/

10/01/2010

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10568654
Filing Date	2007-02-22
First Named Inventor	Michael Patrick Murphy
Art Unit	1614
Examiner Name	Raymond J. Henley III
Attorney Docket Number	110199.405USPC

EXAMINER SIGNATURE

Examiner Signature	/Raymond J. Henley III/	Date Considered	10/01/2010
--------------------	-------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.